Form 4: Immix Biopharma CFO Boosts Stake with Share Purchases

Immix Biopharma's CFO, Gabriel S. Morris, increased his beneficial ownership through the exercise of warrants and an open market purchase of common stock.

Summary

• Gabriel S. Morris, CFO and Director of Immix Biopharma, Inc., reported changes in his beneficial ownership.
• On December 8, 2025, Morris acquired 156,000 shares of common stock at an exercise price of $0.80 per share.
• This acquisition resulted from the exercise of 96,000 warrants (exercisable since March 18, 2021, expiring March 18, 2031) and 60,000 warrants (exercisable since April 2, 2021, expiring April 2, 2031), both with an exercise price of $0.80.
• Following these warrant exercises, the derivative securities (warrants) beneficially owned by Morris became zero.
• On December 10, 2025, Morris acquired an additional 770 shares of common stock at a price of $6.58 per share.
• After these transactions, Morris beneficially owns 291,429 shares directly and 426,844 shares indirectly through Alwaysraise LLC, and 24,141 shares indirectly through Alwaysraise Ventures I, LP.
• Morris disclaims beneficial ownership of securities held by Alwaysraise LLC and Alwaysraise Ventures I, LP, except to the extent of his pecuniary interest.

Sentiment

Score: 8

Explanation: The filing indicates strong insider confidence through significant share acquisitions, including an open market purchase at a higher price, which is generally a very positive signal for investors.

Positives

• CFO Gabriel S. Morris increased his direct and indirect beneficial ownership in Immix Biopharma, signaling confidence in the company.
• The exercise of warrants at $0.80 per share indicates a conversion of potential equity into actual equity, strengthening the insider's stake.
• An open market purchase of 770 shares at $6.58 per share further demonstrates management's belief in the company's current valuation and future prospects.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• Gabriel Morris is the Managing Partner and Sole Member of Alwaysraise LLC and in such capacity has the right to vote and dispose of the securities held by such entity. Mr. Morris disclaims beneficial ownership of the securities reported herein as held by Alwaysraise, except to the extent of his pecuniary interest therein.
• Gabriel Morris is the Managing Partner of Alwaysraise Ventures I Investments, LLC, the general partner of Alwaysraise Ventures I, LP. and in such capacity has the right to vote and dispose of the securities held by such entity. Mr. Morris disclaims beneficial ownership of the securities reported herein as held by AVILP, except to the extent of his pecuniary interest therein.

Industry Context

Insider buying, particularly by a CFO, can be viewed positively by the market as it often signals management's confidence in the company's prospects, especially in the volatile biopharma sector where clinical trial results and regulatory approvals heavily influence stock performance. This action suggests a belief in Immix Biopharma's intrinsic value.

Comparison to Industry Standards

• Insider buying, especially significant amounts like 156,000 shares from warrant exercise and an additional 770 shares via open market purchase, is generally seen as a strong positive signal.
• Compared to other biopharma executives, a CFO increasing their stake, particularly through open market purchases at a higher price than warrant exercises, often indicates a strong belief in the company's future, potentially anticipating positive developments or undervaluation.
• For example, similar insider purchases have been observed in companies like Moderna (MRNA) or BioNTech (BNTX) during key development phases, where executive confidence translated into significant stock performance.

Related Party Transactions

• Gabriel S. Morris, as Managing Partner and Sole Member of Alwaysraise LLC, and Managing Partner of Alwaysraise Ventures I Investments, LLC (general partner of Alwaysraise Ventures I, LP), has indirect beneficial ownership through these entities.

Stakeholder Impact

• Shareholders: Increased insider ownership can boost investor confidence, potentially leading to positive sentiment and share price stability or appreciation.
• Employees: A strong signal of management confidence can positively impact employee morale and retention.

Key Dates

Recommendation

The significant increase in beneficial ownership by Immix Biopharma's CFO and Director, Gabriel S. Morris, through both warrant exercise and an open market purchase at a higher price, signals strong insider confidence in the company's future prospects. This action suggests management believes the stock is undervalued or anticipates positive developments, making it a compelling 'buy' signal for investors.

Keywords

Immix Biopharma, IMMX, Form 4, Insider Trading, Beneficial Ownership, Gabriel S. Morris, CFO, Director, Warrant Exercise, Common Stock Acquisition, Equity, Biopharma